Inhibitors of human tumor-expressed CCXCKR2
US7649011B2 · kind B2 · utility
0Cited by
15References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 22, 2003 |
| Grant date | Jan 19, 2010 |
| Priority date | — |
| Expiry date | Sep 29, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.